Abstract. Bacillus Calmette-Guérin (BCG) is the most effective treatment for superficial and in situ transitional bladder cancer. Although the complete mechanisms for its effect are not fully understood yet, both immunological and direct effects on tumor cells have been proposed. It has been proposed that apoptotic tumor cells could be better inducers of immunity than necrotic ones. Thus, apoptosis of bladder cancer cells could contribute to a global response to BCG. Lysosomal hydrolase cathepsin B (CB) is involved in the apoptotic process and has a key role in breast cancer cell programmed death through the activation of a pro-apoptotic protein BID. Truncated BID participates in the mitochondrial apoptotic pathway that involves the activation of pro-caspase 9. The possibility that CB can be involved in apoptosis of TCC line has not been explored yet. Therefore, we analyzed the participation of CB in BCG-induced apoptosis of human and murine TCC lines. Apoptosis was evaluated by a morphologic assay and CB activity by a substrate-specific colorimetric method. Expression of CB, BID and pro-caspase 9 was determined by Western blotting. BCG induced apoptosis of murine (MBT2, MB49) and human (T24) TCC lines. An increase in both CB activity and protein was also observed. The apoptosis of T24 and MB49 cell lines was mediated by activation of pro-caspase 9 and BID, both proteins are involved in mitochondrial apoptosis. Apoptosis and activation of pro-caspase 9 and BID were inhibited by CA074Me (CA), a cell permeable CB inhibitor. Thus, CB is involved in BCG-induced apoptosis of TCC lines, using at least in part the mitochondrial pathway.
Introduction
Intravesical administration of attenuated bacillus CalmetteGuérin (BCG) plays a major role in the treatment and prophylaxis of recurrent superficial and in situ bladder carcinoma (1) . Recent meta-analyses have shown that BCG is better than other intravesical chemotherapeutic agents for prevention of tumor recurrence. In addition, BCG is the only intraluminal therapy that has been demonstrated to decrease the risk of tumor progression to muscle invasion (2) .
Despite this therapeutic advantage of intravesical BCG, a significant number of patients fail to respond and present disease recurrence or progression (3) . Efforts to improve treatment outcomes with BCG depend on a clear understanding of the sequence of events through which BCG exerts its antitumor activity.
The exact mechanism of the anti-tumor activity is not completely understood, but it is well known that BCG evokes an early local immune cell reaction, which includes an increase in the MHC complex and cytokine production and finally in the Th1 cell-regulated cytotoxicity towards TCC (4) .
A direct interaction between tumor cells and BCG has also been described. Internalized and degraded BCG has been identified in urothelial cells both in vitro and in vivo (5) . BCG induces surface antigen expression on bladder tumor cells (6) and growth inhibition of bladder cancer cell lines in vitro (7) . Other mycobacteria have been implicated in apoptosis induction of their target cells (8, 9) and the induction of bladder cancer cell apoptosis by INF, which is induced by BCG, has also been documented (10) . However, the possibility that BCG can also directly induce apoptosis in bladder cancer cells has not been addressed.
Apoptosis is a physiological process that regulates homeostasis of different tissues by eliminating cells and that is downregulated in tumor cells (11) . Initiation and execution phases of apoptosis require the activation of cysteine proteases of the caspase family. Two major pathways of apoptosis have been described: the extrinsic one, which takes place by the activation of the death receptor and is initiated by caspase 8; and the intrinsic or mitochondrial one, which involves procaspase 9 activation (12 hydrolase has recently been involved in the apoptotic process as well (13, 14) . More recently, it has been reported that CB has a key role in breast cancer cell programmed death through the activation of BID, a proapoptotic member of the Bcl-2 family (15) . The possibility that CB can be involved in apoptosis of bladder cancer cells has not yet been explored. Thus, we analyzed the participation of CB in BCG-induced apoptosis of human and murine bladder cancer cell lines. Rabbit polyclonal anti-murine CB (FL-339) sc-13985, anti-BID (FL-195) sc-11423 and anti pro Caspase 9 P 35 (H-170)-SC8355, were obtained from Santa Cruz Biotechnology, USA. Anti-actin antibody (Ab Mo 090M) was purchased from Biogenex (San Ramon, CA).
Materials and methods

BCG.
Determination of TCC line growth. Cell suspensions of 1x10
5 cells/ml were seeded in 96-well (200 μl) or in 6-well plates (2 ml) (Greiner Labortechnik GmbH, Frickenhausen, Germany) and cultured at 37˚C in a 5% CO 2 humidified atmosphere up to 70-80% confluence (24 h of incubation). Different amounts of BCG (from 0.01 to 2 mg/ ml) were added for 2 h and then eliminated by washing with phosphate buffered solution. After 24 h, cytostatic/cytotoxic effects were assessed by a non-radioactive cell titer MTS in 96-well plates, and by counting the number of cells in the 6-well plates.
Determination of apoptosis and necrosis. Tumor cells were seeded on cover slides in 6-well plates, treated with BCG (2 mg/ml) for 2 h, and then washed. The CB catalytic inhibitor CA074Me (CA) (10 μM) was also added. After 24 h, cells adhered to cover slides and present in supernatants were stained with acridine orange (10 μg/ml) plus ethidium bromide (10 μg/ml). Cells with green fluorescence and condensed chromatin were recorded as apoptotic while orange cells with lax chromatin were recorded as necrotic cells.
Determination of CB expression. Expression of CB was determined as previously described (16) . Briefly, T24 and MB49 cell lines treated for 2 h either with or without BCG (2 mg/ml) were gently washed and after 24 h minced in buffer [50 mM Tris-HCl (pH 8.0); 100 μM NaCl; 1% Triton, 1 μM/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ ml leupeptin and 10 mM EDTA/EGTA] at approximately 30x10 6 cell/ml. After disruption with two cycles of ultrasound, 80% of potency during 3 sec (Vibra Cell™, Sonic and Matherials Inc., Danbury, CT, USA), samples were centrifuged for 10 min at 13,000 x g. Protein content was determined in the resultant supernatant fluids by the Bradford method, 25 μg of protein was heated at 95˚C for 3 min in Laemmli buffer and electrophoresis was performed on 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) (17) . Different concentrations of CB (12.5 and 25 μg/ml) were simultaneously seeded. After electrophoresis, proteins were transferred to PVDF membranes and specific immunodetection was performed. Human and murine CB proteins were revealed with the NBT/BCIP and ECL method, respectively.
CB activity assay. Activity of CB (EC: 3.4.23.1) was determined in T24 and MB49 cell lines after 2, 4 and 24 h of treatment with or without BCG (2 mg/ml) by a colorimetric method (absorbance 520 nm) as previously described by Barrett et al (18) employing a specific substrate (N-CBZVal-Lys-Lys-Arg-4-methoxy ß-naphtilaminde). Different concentrations of purified papain (EC: 3.47.22.2) were used to build a standard curve.
Determination of pro-caspase 9 and BID. Expression of both proteins was determined by Western blot assay. In this case only the human T24 and murine MB49 line were used. TCC cell lines were treated with BCG as described above with or without CA (10 μM). At different times after BCG washing, cells were scraped and samples were prepared as previously described for the expression of CB. Samples were electrophoresed on 10% of SDS-PAGE and then transferred to PVDF membranes. Immunoreactive proteins were detected with the ECL method employing a solution of Tris (0.1 M) plus luminol (124 mM), p-coumarinic acid (200 mM) and H 2 O 2 (100 vol., 1:2500).
Statistical assays. Data were reported as mean ± SD of four replicates per group. Significance of differences was calculated by one-way ANOVA and Bonferroni contrast by using Graph Pad InStat statistical package (version 3.01). Independent experiments were performed at least 3 times with similar results. Herein, we show one representative of three experiments.
Results
In vitro inhibition of TCC growth by BCG. Subconfluent monolayers of bladder cancer cells treated with different concentrations of BCG showed a dose-dependent growth inhibition. Significant inhibition was observed for concentrations of BCG ≥0.5 and 1 mg/ml for MB49 and T24, respectively (p<0.01), being the ID50 for MB49 0.5 mg/ml, while for T24 cells it was even >2.5 mg/ml (Fig. 1A) .
BCG induces an increase in both the expression and activity of CB in TCC. Determination of intracellular CB with a specific antibody showed that both the human T24 and the murine MB49 cell lines expressed the 33-kDa single-stranded CB (CB 33 ) and the 29-27-kDa heavy chain of the double-stranded CB (CB ). Both CB 33 and CB 29-27 increased after BCG treatment (Fig. 1B and C, respectively) . Increase in CB activity was observed as early as after 2 h, remaining elevated up to 24 h (p<0.01), and being inhibited by CA (p<0.01) (Fig. 1D) .
CB is involved in TCC growth inhibition induced by BCG.
To investigate if CB was involved in BCG-induced cell growth inhibition, a new set of experiments were carried out with CA, the CB cell permeable inhibitor. Fig. 2 shows that CA (10 μM) blocked the inhibitory effect of BCG (2 mg/ml) on T24, MB49 (p<0.001) and MBT2 (p<0.01) cell viability, as determined by the MTS assay. Similar results were observed by cell number counting (data not shown). These results indicate that CB activity is involved in BCG's inhibitory effect.
BCG-induced TCC apoptosis is dependent on CB.
After BCG treatment of T24, MB49 and MBT2 cells, apoptotic but not necrotic cells were observed (Fig. 3A) . The percentage of apoptotic cells that remained adhered after BCG treatment was significantly higher than in controls (p<0.001), a result reversed by CA (p<0.05) (Fig. 3B1) . Apoptotic cells were also recorded in supernatants showing similar results (Fig. 3B2) . The results suggest that CB is involved in the induction of apoptosis by BCG.
BID and pro-caspase are activated by CB.
To investigate whether the intrinsic pathway of apoptosis was activated by CB, we measured the activation of BID and pro-caspase 9 in T24 and MB49 cells (Fig. 4) . In MB49 cells, the expression of BID (p22) diminished between 2 and 4 h, being undetectable 3-4 h later when truncated BID (p15) was expressed. CA inhibited the vanishing of p22 and the rise of p15 BID. Vanishing of pro-caspase 9 was detected after 1 h and this effect was also blocked by CA. Similar results were found in T24 cells (Fig. 4) . Vanishing of BID (p22) started at 1 h, but truncated p15 could not be detected, and pro-caspase 9 was diminished up to 0.5 h.
Discussion
Intravesical instillation of BCG is a standard therapy for superficial and in situ bladder carcinoma but its mechanism is not completely understood. Both immunological mechanisms and/or direct effects on tumor cells have been proposed, being the former more extensively studied. The direct effect on tumor cells has been less investigated in part because the immune therapy with BCG is administered after tumor resection, assuming that no tumor cells are present. However, it is possible that an undetectable number of tumor cells remain in the bladder. In light of our findings, the biological behavior of tumor cells to BCG could contribute to the global response. For example, it has been proposed that tumor cell death by apoptosis could be a better inducer of immunity than death by necrosis (19) and that dendritic cells loaded with apoptotic tumor cells are more efficient than dendritic cells loaded with necrotic ones in activating cytotoxic T lymphocytes (20) .
Thus, we studied the effects of BCG on TCC lines by evaluating the participation of lysosomal hydrolase CB in apoptosis induction. BCG induced growth inhibition in a dose-dependent manner from 0.1 mg/ml, reaching a plateau for doses >2 mg/ml. MB49 cells appeared to be more sensitive than T24 cells to BCG inhibition since the ID50s were 0.5 mg/ ml and >2.5 mg/ml, respectively. The BCG concentration used was in the therapeutic range, since 2x10 6 CFU/ml was indicated for human bladder instillation.
In agreement with other authors (6,21), we observed that the T24 and MB49 cells were capable of internalizing BCG (data not shown). In addition, it has been reported that bladder tumor cells are capable of antigen presentation and induction of an immune response upon BCG treatment (6) . As internalization and antigenic presentation depend on lysosomal pathway, and CB is the main lysosomal hydrolase involved in MHC II antigen presentation (22), we believe that CB could participate in the inhibition of cellular growth. CB protein increased concomitantly with inhibition of cell growth after BCG treatment. An increase in the 33-and 29-27-kDa bands corresponding to the active forms of CB was detected. CB activity was also increased up to 2 h after BCG addition, and CA, a specific cell permeable CB inhibitor (23) blocked not only CB activity but also reversed BCG-induced cell growth inhibition. Thus, our results show that CB participates in the inhibition of TCC growth induced by BCG.
Since induction of apoptosis by different mycobacteria in other experimental models has been already described (8, 9) and that Mycobacterium Philei cell wall complex directly induces apoptosis in human bladder cancer cells (24), we studied whether BCG can also induce TCC apoptosis. Our results showed that BCG induced apoptosis in the three TCC lines assayed, and that CB participated in this process since it was blocked by CA.
Two initiation pathways, triggered by separate events, converge to execute apoptosis: the extrinsic one, which depends on extracellular binding to death receptors and activation of caspase 8; and the intrinsic one, which produces changes in the mitochondrial membrane potential with release of cytochrome c and activation of pro-caspase 9 (25) .
It has been described that CB contributes to hepatocyte apoptosis by promoting mitochondrial release of cytochrome c (26) . CB has also been involved in programmed death of human breast cancer cells MCF-7 by activating BID (26) , suggesting that CB could participate in the intrinsic pathway. To test this possibility, we evaluated whether the activation of BID and pro-caspase 9 could be detected in our TCC cell lines. Our results showed that BCG induced activation of BID and pro-caspase 9 in both T24 and MB49 cells and that this induction was mediated by CB because it could be inhibited by CA. However, some points need further consideration. First, the kinetics of BID activation is different between MB49 and T24 lines. In MB49, BID begins to disappear at 2 h and is undetectable after 3 h or 3.5 h, while in T24, a light vanishing was detected at 1 h, which was constant for at least 6 h (data not shown). In MB49, truncated BID (p15) was detected at 3.5 h while in T24 it was undetected at least up to 6 h post-BCG addition (data not shown). This difference could be related to the fact that BCG-induced growth inhibition was higher in MB49 than in T24 lines. However, we cannot discard the fact that it can also be due to a different sensitivity of the antibody to murine and human cell lines. Second, our results showed that the activation of pro-caspase 9 precedes that of BID. If activation of BID by CB and the subsequent activation of the mitochondrial pathway were the only mechanisms, BID activation should precede pro-caspase 9 activation. Thus, other mechanisms must be involved in the activation of pro-caspase 9. Other proteins of the BID family such as Bax/Bak or other caspases could be involved in activating the mitochondrial pathway. For example, it has been reported that caspase-2 may be responsible for direct permeabilization of mitochondria, while in other instances, it may act in conjunction with Bax/Bak to amplify cytochrome c release (27) .
It has recently been published that proteasome inhibitors can induce CB release, caspase 2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells (28) . Furthermore, CB could be involved in the direct activation of pro-caspase 9 or, alternatively, as described in fibrosarcoma cell apoptosis induced by TNF (14) , CB could act as a dominant executer protease inducing apoptosis of TCC.
Taken into account that apoptosis is a good inductor of immunity we can speculate that the patients whose tumor cells did not undergo apoptosis after BCG therapy, could be refractory or less sensible to this immune therapy. However, to arrive at this hypothesis it is necessary to know the complete mechanisms through which BCG exerts its antitumor activity. We propose that the increase in CB activity is involved in apoptosis of TCC lines induced by BCG. CB is able to activate BID and pro-caspase 9, both proteins involved in the mitochondrial apoptotic pathway. The crosstalk between the extrinsic and mitochondrial apoptotic pathways as well as the participation of CB as a dominant executer protease awaits further investigation. To our knowledge, this is the first report showing that CB is involved in TCC apoptosis.
